These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Kollmeier MA; Katz MS; Mak K; Yamada Y; Feder DJ; Zhang Z; Jia X; Shi W; Zelefsky MJ Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):713-8. PubMed ID: 20452139 [TBL] [Abstract][Full Text] [Related]
12. Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. D'Amico AV J Clin Oncol; 2010 Jun; 28(16):2651-2. PubMed ID: 20421530 [No Abstract] [Full Text] [Related]
13. Prostate-specific antigen: a misused and maligned prostate cancer biomarker. Thompson IM; Tangen CM; Kristal AR J Natl Cancer Inst; 2008 Nov; 100(21):1487-8. PubMed ID: 18957671 [No Abstract] [Full Text] [Related]
14. Editorial comment to association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. Shimbo M Int J Urol; 2012 Aug; 19(8):747-8. PubMed ID: 22651131 [No Abstract] [Full Text] [Related]
15. Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Stephan C; Jung K Eur Urol; 2008 Aug; 54(2):369-70. PubMed ID: 18006212 [No Abstract] [Full Text] [Related]
16. Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Froehner M Eur Urol; 2008 Aug; 54(2):368-9. PubMed ID: 18006213 [No Abstract] [Full Text] [Related]
17. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eggener S Eur Urol; 2009 Mar; 55(3):616. PubMed ID: 18639973 [No Abstract] [Full Text] [Related]
18. Editorial Comment to Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer. Yashi M Int J Urol; 2015 Jun; 22(6):561-2. PubMed ID: 25799888 [No Abstract] [Full Text] [Related]
19. Editorial comment on: current applications for prostate-specific antigen doubling time. Semjonow A Eur Urol; 2008 Aug; 54(2):301. PubMed ID: 19209420 [No Abstract] [Full Text] [Related]
20. Editorial comment on: current applications for prostate-specific antigen doubling time. O'Brien MF Eur Urol; 2008 Aug; 54(2):300-1. PubMed ID: 19209419 [No Abstract] [Full Text] [Related] [Next] [New Search]